

## ASX RELEASE

### Relief from Quarterly Reporting

Wellington, NZ, 19 October 2023: Volpara Health Technologies Ltd. ("Volpara," "the Group," or "the Company"; ASX:VHT), a global leader in software for the early detection of breast cancer, advises that ASX has exercised its discretion to lift the requirement for the Company to lodge quarterly cash flow and activities reports under Listing Rules 4.7B and 4.7C due to its record of positive net operating cash flows over the past 12 months.

Volpara will now lodge preliminary final reports (Appendix 4E) and half yearly reports (Appendix 4D) within two months of the end of the relevant reporting period. The Company's next periodic report will be the half year report for the period ending 30 September 2023 due no later than 30 November 2023.

While Volpara is no longer required to submit quarterly reports, the Company remains committed to providing regular operational and financial updates to its shareholders and will therefore release business updates periodically. In addition to sharing substantive news with investors that impact Volpara's business and revenue, Volpara will also release individual announcements for large sales.

### Authorisation & Additional Information

This announcement was authorised by the CEO & MD of Volpara Health Technologies Limited.

## ENDS

### For further information, please contact:

#### Corporate Enquiries

Teri Thomas, CEO & MD

Volpara Health Technologies

[Teri.thomas@volparahealth.com](mailto:Teri.thomas@volparahealth.com)

t: +64 4 499 6029

#### Investor Relations

Hannah Howlett

WE Communications

[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

t: +61 4 5064 8064

#### Media Enquiries

Trevor Chappell

WE Communications

[tchappell@we-worldwide.com](mailto:tchappell@we-worldwide.com)

t: +61 407 933 437

### About Volpara Health Technologies Limited (ASX:VHT)

Volpara Health Technologies makes software to save families from cancer. We help leading healthcare providers positively impact communities around the world. They use Volpara solutions to better understand cancer risk, empower patients in personal care decisions, improve and maintain quality, and guide recommendations about additional imaging, genetic testing, and other interventions.

Our focus on customer value means that our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. In an industry facing increasing staff shortages, our software helps streamline operations and provides key performance insights that support continuous quality improvement.

A Certified B Corporation, Volpara is the preferred partner of leading healthcare institutions around the world. It maintains the most rigorous security certifications and holds over 100 patents and numerous regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, Volpara has raised A\$132 million. Volpara is based in Wellington, New Zealand, with an office in Seattle.

For more information, visit [www.volparahealth.com](http://www.volparahealth.com)